Go Pro
NASDAQ:VANI

Vivani Medical Q2 2025 Earnings Report

Vivani Medical logo
$1.24 0.00 (0.00%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$1.22 -0.02 (-1.53%)
As of 09/25/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vivani Medical EPS Results

Actual EPS
-$0.12
Consensus EPS
-$0.10
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Vivani Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vivani Medical Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 13, 2025
Conference Call Time
12:00AM ET

Upcoming Earnings

Vivani Medical's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Vivani Medical Earnings Headlines

Buffett's Final Warning: "The Dollar Is Going to Hell"
On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses.tc pixel
Vivani Medical Inc U5P
See More Vivani Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vivani Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vivani Medical and other key companies, straight to your email.

About Vivani Medical

Vivani Medical (NASDAQ:VANI) (NASDAQ: VANI) is a biopharmaceutical company developing miniature, long-term implantable drug-delivery systems for chronic diseases. Its proprietary NanoPortal technology is designed to deliver medication continuously over extended periods, potentially reducing the need for frequent injections or daily dosing.

The company’s pipeline has focused primarily on treatments based on glucagon-like peptide-1 (GLP-1) therapies. Its lead candidates have included NPM-115, an implantable formulation of exenatide being developed for chronic weight management, and NPM-119, an exenatide-based implant intended to treat type 2 diabetes. Vivani has also evaluated additional applications of its implant technology for other metabolic and chronic conditions.

Vivani is headquartered in Fremont, California, and its development activities have primarily been directed toward the U.S. pharmaceutical and biotechnology market. The company originated from Nano Precision Medical, Inc. and became a publicly traded company through a business combination involving Second Sight Medical Products. Vivani is led by President and Chief Executive Officer Adam Mendelsohn, Ph.D.

View Vivani Medical Profile